40
24
0
Safety of Simtriyo was studied over 52 weeks in children and adolescents4
center
text-brand-navy
font-weight-extrabold
site-h2
80
24
0
custom
2.55fr 7.70fr
1
1
custom
40px
none
custom
24px
stretch
left
false
40
24
0
false
40px
24px
Open-label extension study design
- Primary endpoint: Long-term safety and tolerability of Simtriyo, administered to pediatric patients (aged 6-17 years)4
- Patients were either rollover subjects from double-blind parent trials or enrolled as de novo subjects4
- Exploratory efficacy was assessed using the ADHD-RS-5 and Conners 3-P(S)
custom
small-heading,asymmetric-border-radius,disable-texture